Why did the CSL share price sink 10% in June?

CSL shares were out of form in June. But why were investors hitting the sell button?

Key points
  • CSL shares were sold off in June
  • This was driven by the release of a disappointing market update
  • CSL revealed FY 2024 profit guidance well short of what the market was expecting

The CSL Limited (ASX: CSL) share price had a tough time in June.

During the month, the biotherapeutics giant's shares lost approximately 10% of their value.

As a comparison, the S&P/ASX 200 Index (ASX: XJO) rose 1.6% over the same period.

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.

Image source: Getty Images

Why did the CSL share price tumble in June?

Investors were selling down the CSL share price in June after the company released a disappointing market update.

That update revealed that management now expects a foreign currency headwind of US$230 million to US$250 million in FY 2023. This is up from its previous estimate of US$$175 million for the 12 months.

And while its constant currency profit guidance for FY 2023 was unchanged and is actually now skewed to the top end of its guidance range, comments about its expectations for the following year overshadowed this.

Management advised that it is projecting profit growth of ~13% to 18% to the range of ~US$2.9 billion and US$3 billion in constant currency in FY 2024.

This was well short of expectations, with the market previously believing that favourable plasma collection tailwinds were going to support margin expansion and drive even stronger growth.

Commenting on the update, analysts at Citi said:

CSL increased the FX headwind guidance for FY23 and provided FY24 NPATA guidance which was ~12% below VA consensus.

The trading update was about resetting the market's expectations for the recovery of gross margins in the Behring division, as both donor fees and labour cost inflation remain higher than anticipated. CSL now expects Behring GM to recover to pre-covid levels in 3-5 years (FY26-28) – the market was expecting a sharper recovery by FY26. We now expect FY27.

Nevertheless, the broker believes that this selloff has created a buying opportunity for investors. It retained its buy rating with a trimmed price target of $340.00. It added:

We cut our above market FY23-25e NPATA per share (Core EPS) by -4%/-17%/-17% and cut our TP to $340 (from $350). Our TP implies CSL should trade on an FY26 PE of ~27x, in line with the 10-year average. Maintain Buy. The next catalyst is the release of the argenx trial data expected in July (argenx CIDP trial data expected in July).

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »